Teladoc Health Stock Forecast, Price & News

31 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teladoc Health in the last year. There are currently 13 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Teladoc Health stock.
View analyst ratings for Teladoc Health or view top-rated stocks.

Wall Street analysts have given Teladoc Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Teladoc Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Teladoc Health saw a decline in short interest in January. As of January 29th, there was short interest totaling 11,740,000 shares, a decline of 22.9% from the January 14th total of 15,230,000 shares. Based on an average daily trading volume, of 3,390,000 shares, the days-to-cover ratio is currently 3.5 days.
View Teladoc Health's Short Interest.

Teladoc Health is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Teladoc Health.

Teladoc Health, Inc. (NYSE:TDOC) announced its quarterly earnings data on Wednesday, February, 24th. The health services provider reported ($3.07) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $2.82. Teladoc Health had a negative trailing twelve-month return on equity of 6.15% and a negative net margin of 12.71%.
View Teladoc Health's earnings history.

Teladoc Health's stock was trading at $137.40 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TDOC shares have increased by 43.0% and is now trading at $196.47.
View which stocks have been most impacted by COVID-19.

Teladoc Health issued an update on its FY 2021 After-Hours earnings guidance on Wednesday, February, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.95-2 billion, compared to the consensus revenue estimate of $1.95 billion.

31 equities research analysts have issued 12-month price targets for Teladoc Health's stock. Their forecasts range from $165.00 to $330.00. On average, they anticipate Teladoc Health's stock price to reach $244.19 in the next year. This suggests a possible upside of 24.3% from the stock's current price.
View analysts' price targets for Teladoc Health or view top-rated stocks among Wall Street analysts.

106 employees have rated Teladoc Health CEO Jason Gorevic on Glassdoor.com. Jason Gorevic has an approval rating of 95% among Teladoc Health's employees. This puts Jason Gorevic in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Teladoc Health include Sanofi (SNY), CSL (CSLLY), Stryker (SYK), AstraZeneca (AZN), GlaxoSmithKline (GSK), Intuitive Surgical (ISRG), Gilead Sciences (GILD), Anthem (ANTM), Zoetis (ZTS), Becton, Dickinson and (BDX), GlaxoSmithKline (GSK), Illumina (ILMN), HCA Healthcare (HCA), Bayer Aktiengesellschaft (BAYRY) and Takeda Pharmaceutical (TAK).
View all of TDOC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teladoc Health investors own include NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Square (SQ), Shopify (SHOP), DocuSign (DOCU), salesforce.com (CRM), PayPal (PYPL) and Zoom Video Communications (ZM).

(TDOC) raised $112 million in an IPO on Wednesday, July 1st 2015. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Teladoc Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."

Teladoc Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include General Catalyst Group Management LLC (5.55%), Baillie Gifford & Co. (4.99%), Jennison Associates LLC (3.84%), Aequim Alternative Investments LP (2.38%), Sumitomo Mitsui Trust Holdings Inc. (2.22%) and Nikko Asset Management Americas Inc. (1.95%). Company insiders that own Teladoc Health stock include Adam C Vandervoort, Andrew Turitz, Arnnon Geshuri, Daniel Trencher, David L Shedlarz, David William Sides, Gabriel R Cappucci, Glen Tullman, Hemant Taneja, Jason N Gorevic, Kenneth H Paulus, Lewis Levy, Mala Murthy, Michael Goldstein, Michelle Bucaria, Peter A Mcclennen, Stephany Verstraete, William H Frist and Yulun Wang.
View institutional ownership trends for Teladoc Health.

TDOC stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jennison Associates LLC, Fiera Capital Corp, Alliancebernstein L.P., Westwood Management Corp IL, Clough Capital Partners L P, Stephens Investment Management Group LLC, and Zweig DiMenna Associates LLC. Company insiders that have sold Teladoc Health company stock in the last year include Adam C Vandervoort, Andrew Turitz, Arnnon Geshuri, Daniel Trencher, David L Shedlarz, David William Sides, Gabriel R Cappucci, Glen Tullman, Hemant Taneja, Jason N Gorevic, Kenneth H Paulus, Lewis Levy, Mala Murthy, Michael Goldstein, Michelle Bucaria, Stephany Verstraete, William H Frist, and Yulun Wang.
View insider buying and selling activity for Teladoc Health or view top insider-selling stocks.

TDOC stock was acquired by a variety of institutional investors in the last quarter, including General Catalyst Group Management LLC, Aequim Alternative Investments LP, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Baillie Gifford & Co., Norges Bank, Discovery Value Fund, and Hitchwood Capital Management LP.
View insider buying and selling activity for Teladoc Health or or view top insider-buying stocks.

Shares of TDOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TDOC stock can currently be purchased for approximately $196.47.

Teladoc Health has a market capitalization of $28.48 billion and generates $553.31 million in revenue each year. The health services provider earns $-98,860,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

Teladoc Health employs 3,276 workers across the globe.

The following companies are subsidiares of Teladoc Health: AM Healthcare Management Consulting Sdn. Bhd., AMHMS - Health Care Management Services S.A., Advance Holdco Limited, Advance Medical, Advance Medical - Serviços de Consultoria e Gestão de Dados Ltda, Advance Medical Health Care Management Services Chile S.A., Advance Medical Hungary Tanácsadó és Szolgáltató Korlátolt Felelösségü Társaság, Advance Medical Inc., AmeriDoc, Best Doctors, Best Doctors Australasia Pty Limited, Best Doctors Holdings Inc., Best Doctors Inc., Best Doctors International Insurance S.a.r.l., Best Doctors Portugal Ltd., BetterHelp, CogCubed, Compile Inc., Consult A Doctor, HY Holdings Inc., Healthiest You, Institute of Patient Safety and Quality in Virtual Care LLC, Intouch Health, Livongo, MedecinDirect, Médecin Direct, Rise Health Inc., Stat Doctors, Stat Health LLC, TELADOC HEALTH INTERNATIONAL SOCIEDAD ANÓNIMA, TelaDietitian, Teladoc Health Canada Inc., Teladoc Health Massachusetts Holdings Inc., Teladoc Health UK Ltd., and Yi Yi Medical Health Management Consulting (Shanghai) Co. Ltd..

Teladoc Health was founded in 2002.

The official website for Teladoc Health is www.teladochealth.com.

Teladoc Health is headquartered at 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577.

Teladoc Health's mailing address is 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577. The health services provider can be reached via phone at 203-635-2002 or via email at [email protected]